Skip to content
Screener

Common Stock at other companies

Amgen logo
AmgenAMGN
2.8B0.0%
Gilead Sciences logo
Gilead SciencesGILD
5.6B0.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
200M0.0%
Biohaven logo
BiohavenBHVN
200M0.0%
Assembly Biosciences logo
Assembly BiosciencesASMB
$16K+100%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$1.44B+2.0%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.49B+153%
Enterprise value$1.3B+235%
P/S4.9×-26.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemJune 30,2026December 31,2025
Commitments and contingencies (Note 7)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 169,185,671 and 139,474,954 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1714
Additional paid-in capital2,230,4641,965,090
Accumulated other comprehensive loss(4,602)(2,057)
Accumulated deficit(1,243,386)(1,197,771)
TOTAL STOCKHOLDERS’ EQUITY982,493765,276

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s common stock?
Vir Biotechnology, Inc. (VIR) reported common stock of 300M in Q2 2026.
How has Vir Biotechnology, Inc.'s common stock changed year-over-year?
Vir Biotechnology, Inc.'s common stock decreased by 0.0% year-over-year, from 300M to 300M.
What is the long-term trend for Vir Biotechnology, Inc.'s common stock?
Over 5 years (2020 to 2025), Vir Biotechnology, Inc.'s common stock has grown at a 645.8% compound annual growth rate (CAGR), from 13K to 300M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Vir Biotechnology, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude